Sign inJoin waitlistJoin the waitlist

AK

Adel Kardosh

Medical Director of Clinical Research, OHSU Knight Cancer Institute, School of Medicine · Oregon Health & Science University

Credentials: · · · · ·

History

OHSU Knight Cancer Institute Center · Oregon Health & Science University
Present
Oregon Health & Science University
Present

Hematology and Medical Oncology
2014–2017
Internal Medicine
University of Southern California/Los Angeles General Medical Center
2012–2014
University of Southern California, Keck School of Medicine
Keck Sch of Med of the Univ of Southern Calif
2007–2011

Research

Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2…
The Lancet Oncology · 2023 · 214 citations
Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors
Blood · 2009 · 185 citations
HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress
Cancer Research · 2007 · 117 citations

CL
Charles Lopez
21 papers
EC
Emerson Chen
20 papers · 1 as a fellow
Skye Mayo
15 papers
NN
Nima Nabavizadeh
14 papers
Thomas Chen
12 papers
BS
Brett Sheppard
6 papers
Charles Thomas
6 papers
FR
Flavio Rocha
6 papers
Gordon Mills
6 papers
GP
Guillaume Pegna
6 papers · 1 as a fellow
PP
Peter Pyrko
6 papers
TS
Thomas Sutton
6 papers · 5 as a resident

Clinical trials

Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma
Principal investigator · Not yet recruiting · Phase 2
OHSU Knight Cancer Institute
2026–2027
Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma
Principal investigator · Withdrawn · Phase 2
OHSU Knight Cancer Institute
2022–2027
Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer
Principal investigator · Recruiting
OHSU Knight Cancer Institute
2021–2027
Electromagnetic Fields Versus Placebo For Child-Pugh A and B Patients With Advanced Hepatocellular Carcinoma
Site PI · Unknown · Phase 2, Phase 3
THERABIONIC INC.
2023–2024